Investor Presentaiton slide image

Investor Presentaiton

India Business India Business: Q3FY22 Sales of 18,156 million (19.9% YoY growth) . India sales contributed 70.2% to total sales in Q3FY22 . . • In 9MFY22, the Company's secondary sales grew by 31.7% YoY compared to IPM growth of 21.1% YoY (Source: IQVIA data) Growth was mainly led by acute therapies like anti-infectives, vitamins / minerals / nutrients, gastrointestinal and pain management segment helped by COVID-19 tailwinds During 9MFY22, the Company also outperformed IPM in the chronic therapies like neuro / CNS, cardiac, anti-diabetes and derma Company's Trade Generic business delivered a robust growth during the quarter and nine months, despite the high base of last financial year Q3FY22 - India Sales (* mn) 9MFY22 - India Sales (* mn) 15,140 YOY: 19.9% 18,156 42,264 YoY: 34.5% 56,858 Q3FY21 Q3FY22 9MFY21 9MFY22 O e ALKEM
View entire presentation